GBGiancarlo Balbi

Giancarlo Balbi

*This is an algorithmically generated author record based on publicly available information.

Giancarlo Balbi has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Undifferentiated pleomorphic sarcoma with osteoclast-like giant cells of the female breast

    by Giancarlo Balbi, Luca Di Martino, GianPaolo Pitruzzella, Diego Pitruzzella, Flavio Grauso, Antonella Napolitano, Elisabetta Seguino, Francesco Gioia, Pasquale Orabona

    The authors describe a case of undifferentiated pleomorphic sarcoma of the breast occurring in a 50-year-old woman who presented with a palpable mass in her right breast. She first noticed the mass one month previously. Core needle biopsy showed connective tissue including epithelioid and spindle cells. The patient underwent total mastectomy without axillary lymph node dissection. Based on examination of the excised tumor, the initial pathologic diagnosis was atypical spindle-shaped and ovoid cells with uncertain malignant potential. Histological findings with immunomarkers led to the final diagnosis of undifferentiated pleomorphic sarcoma.


    • 1 January 2012
      • Vol. 39  (3) , 321-5

    The role of hypertension, body mass index, and serum leptin levels in patients with endometrial hyperplasia during premenopausal period.

    by G Balbi, A Napolitano, E Seguino, G Scaravilli, F Gioia, L Di Martino, D Fusco, G Signoriello, F Grauso

    To investigate whether body mass index (BMI), hypertension (HTN), diabetes, age, and physical activity can be considered risk factors for endometrial simple hyperplasia in premenopausal women. Furthermore this study was undertaken to determine whether serum concentration of leptin in patients with BMI>or= 30 kg / m2 with endometrial hyperplasia deviate from values in patients with normal endometrium. The authors enrolled 167 hyperplasia cases and 282 controls. Demographic characteristics and data on age, diabetes, hypertension, BMI, physical activity, and anthropometric parameters were collected. Leptin concentration in serum was measured with immunoenzymatic test kit from IBL. Univariable and multivariable analysis were performed to verify the association among age, HTN, BMI, physical activity, diabetes, and the presence of uterine hyperplasia. Furthermore the authors evaluated the correlation between BMI and leptin level (with Pearson's linear correlation) in women with simple hyperplasia and in controls. The prevalence of hyperplasia found was 34.4%. The following factors were independently associated with increased risk of endometrial hyperplasia: HTN (odds ratio 3.19, 95% confidence interval 1.20-8.48, por=30 Kg/m2 (odds ratio 6.43, 95% confidence interval 3.92-10.53, por=30 kg/m2 and HTN (blood pressure>or=130/85 or in therapy). Leptin appears to participate in proliferative processes of the endometrium, depending on BMI. Current guidelines may need to be reconsidered.


    • 1 January 2012
      • Vol. 33  (5) , 467-471

    Role of the association of high-risk HPV identified by real-time PCR in cervical preneoplastic lesions

    by G. Balbi, A. Napolitano, F. Giordano, S. Capuano, M. A. Manganaro, L. Di Martino, D. Fusco, F. Grauso, E. Seguino

    Objective: To evaluate the effects of infection in multiple types of high-risk human papilloma virus (HPV) in cervical preneoplastic lesions in patients undergoing colposcopy following a diagnosis of atypical squamous cells of unknown significance (ASCUS) and low-grade squamous intraepithelial (LSIL) cytology. Materials and Methods: Between 2009 and 2010, 2,500 patients were recruited with a mean age of 35 +/- 5 years. Screening for cervical cancer was performed and in case of ASCUS and LSIL the patients underwent colposcopy. The tests for the detection and typing of viral DNA (HPV - DNA test) were performed on cervical swab with real-time PCR amplification. Results: The prevalence of infection was 70% (1579/2256) in the patients recruited. In relation to the degree of preneoplastic lesions some high-risk HPV viral genotypes were identified: HPV 16 (319/1466), HPV 18 (164/1466). HPV 45 (76/1466), HPV 31 (215/1466), HPV 52 (145/1466), HPV 58 (55/1466) HPV 56 (79/1466), HPV 51 (110/1466), HPV 6 (138/1466), HPV 11 (88/1466), HPV 42 (34/1466), HPV 53 (43/1466). In case of high-grade lesions of CIN (CIN2 and CIN3) a greater HPV co-infection was detected and in particular the association from 16 to 18 (70%), 16-33 (18%) and 16 to 52 (12%). Conclusions: Infection caused by the simultaneous presence of multiple HPV genotypes appears to be associated with a significantly increased risk of high-grade lesions of CIN or invasive cancer than the presence of single viral infections. The infection with multiple HPV types is a significant risk factor for high-grade lesions of CIN in women undergoing colposcopy for ASCUS cytology / LSIL. The use of real-time PCR has shown the ability not only to identify the different types of HPV, but also to monitor quantitatively the same over time, and during the study phase, to evaluate the sensitivity and specificity of the method in comparison with other techniques.


    • 1 January 2009
      • Vol. 80  (3) , 230-3

    Cytoreductive surgery and ovarian carcinoma.

    by Giancarlo Balbi, Antonietta Monteverde, Isabella Landino, Maria Amparo Manganaro, Ciro Franzese

    The aim of this study is to demonstrate if Cytoreductive surgery in patients with ovarian carcinoma increases overall survival. during the period between 1998 and 2008, 60 patients with a relapse of ovarian cancer, were evaluated in order to undergo a cytoreductive surgery. an optimal cytoreduction (residual disease < 1 cm maximum diameter) was obtained in over half of patients. surgery remains the best therapeutic approach in ovarian cancer since it is associated with an increase in survival in all patients undergoing cytoreduction especially in the advanced stages of the disease. These results and those of other studies allow us to determine which patients may benefit from the cytoreductive surgery, improving their survival rate. A disease-free interval > 12 months is the best predictive factor of improved survival rate after surgery.

    • 1 January 2009
      • Vol. 30  (3) , 289-91

    Ovarian cancer: lymph node metastases.

    by G Balbi, M A Manganaro, A Monteverde, I Landino, Ciro Franzese, F Gioia

    To analyze pelvic and paraaortic lymph node involvement in epithelial ovarian cancer. Between 1995 and 2006, 60 patients with FIGO Stages II, III, IV epithelial ovarian cancer underwent surgical treatment, including systematic pelvic and paraaortic lymphadenectomy. Aortic lymph node metastases were documented in 45 (75%) patients and pelvic nodal metastases in 42 (70%). The incidence of paraaortic nodal involvement was 20% (12/60) in the absence of positive pelvic nodes while the incidence of pelvic nodal involvement was 15% (9/60) in the absence of paraaortic disease; both pelvic and paraaortic lymph node involvement occurred in 55% of patients. The most frequent groups for nodal metastases are paracaval (56%), externaliliac (60%), and obturator (55%). The rate of nodal involvement is important in ovarian cancer and there is a high prevalence of both pelvic and paraaortic lymph node metastases. For this reason bilateral pelvic and paraaortic lymphadenectomy is necessary for staging and as treatment for micrometastases, also in patients with unilateral tumors.


    • 1 December 2007
      • Vol. 78  (3) , 210-3

    Liposomal doxorubicin: a phase II trial.

    by Giancarlo Balbi, Serena Visconti, Antonietta Monteverde, Maria-Amparo Manganaro, Antonio Cardone

    In patients with disseminated endometrial carcinoma, doxorubicin is used as a single agent or in combination therapy. We have carried out a phase II clinical trial of liposomal doxorubicin in first-line therapy of women with disseminated endometrial carcinoma. Between September 2001 and May 2003, 22 patients with histologically confirmed disseminated endometrial carcinoma, were enrolled in this study. Eleven patients had been previously treated with radiation, none of them had been treated with chemotherapy. Liposomal doxorubicin (40 mg/m2) was intravenously administered at 4 week intervals until toxicity or progression. The most common adverse events were fatigue, anemia, pain, and dermatologic toxicity (EPP). Eight patients (36%) achieved a tumor regression (Complete response, CR 3; Partial response, PR 5), ten (46%) maintained stable disease, and four (18%) experienced increasing disease. Liposomal doxorubicin has a lower cardiologic toxicity than doxorubicin with a similar response rate in patients with disseminated endometrial carcinoma.